BioMarin Pharmaceutical

Intense Pricing Pressures Will Challenge Margins While Novel Therapies Advance

AN

AnalystLowTarget

AnalystLowTarget

Not Invested

Community Contributor

Published

18 Apr 25

Updated

07 May 25

n/a

n/a

AnalystLowTarget's Fair Value

n/a

1Y

-19.4%

7D

-3.8%

Loading

1Y

-19.4%

7D

-3.8%

You can edit this narrative until May 12 6:01 AM. Then, changes will post as Updates.

Author's Valuation

US$67.3920.1% undervalued

AnalystLowTarget Fair Value

Shared on 07 May 25

Fair value Decreased 19%

AnalystLowTarget has decreased revenue growth from 4.9% to 4.0% and decreased future PE multiple from 26.6x to 22.1x.

Shared on 30 Apr 25

Fair value Increased 1.24%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystLowTarget made no meaningful changes to valuation assumptions.